{
  "variants": [
    {
      "variant": "A30P",
      "gene": "SNCA",
      "protein_change": {
        "ref": "A",
        "alt": "P",
        "position": "30"
      },
      "variant_string_id": "SNCA A30P",
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": {
        "step_1": {
          "description": "Defined disease mechanism involving α-Synuclein aggregation and toxicity in Parkinson's disease.",
          "judgment": "Yes"
        },
        "step_2": {
          "description": "Assays (proteasome cleavage, liposome interactions) model α-Synuclein aggregation and toxicity.",
          "judgment": "Yes",
          "next_step": "step_3"
        },
        "step_3": {
          "description": "Basic controls (wildtype vs. mutants) not explicitly stated, but comparisons were made.",
          "judgment": "No",
          "next_step": "step_3b"
        },
        "step_3b": {
          "description": "Assays (proteasome cleavage, liposome interactions) are standard techniques validated in prior studies.",
          "judgment": "Yes",
          "evidence_strength": "Max PS3_supporting"
        }
      }
    },
    {
      "variant": "E46K",
      "gene": "SNCA",
      "protein_change": {
        "ref": "E",
        "alt": "K",
        "position": "46"
      },
      "variant_string_id": "SNCA E46K",
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": {
        "step_1": {
          "description": "Defined disease mechanism involving α-Synuclein aggregation and toxicity in Parkinson's disease.",
          "judgment": "Yes"
        },
        "step_2": {
          "description": "Assays (proteasome cleavage, liposome interactions) model α-Synuclein aggregation and toxicity.",
          "judgment": "Yes",
          "next_step": "step_3"
        },
        "step_3": {
          "description": "Basic controls (wildtype vs. mutants) not explicitly stated, but comparisons were made.",
          "judgment": "No",
          "next_step": "step_3b"
        },
        "step_3b": {
          "description": "Assays (proteasome cleavage, liposome interactions) are standard techniques validated in prior studies.",
          "judgment": "Yes",
          "evidence_strength": "Max PS3_supporting"
        }
      }
    },
    {
      "variant": "A53T",
      "gene": "SNCA",
      "protein_change": {
        "ref": "A",
        "alt": "T",
        "position": "53"
      },
      "variant_string_id": "SNCA A53T",
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": {
        "step_1": {
          "description": "Defined disease mechanism involving α-Synuclein aggregation and toxicity in Parkinson's disease.",
          "judgment": "Yes"
        },
        "step_2": {
          "description": "Assays (proteasome cleavage, liposome interactions) model α-Synuclein aggregation and toxicity.",
          "judgment": "Yes",
          "next_step": "step_3"
        },
        "step_3": {
          "description": "Basic controls (wildtype vs. mutants) not explicitly stated, but comparisons were made.",
          "judgment": "No",
          "next_step": "step_3b"
        },
        "step_3b": {
          "description": "Assays (proteasome cleavage, liposome interactions) are standard techniques validated in prior studies.",
          "judgment": "Yes",
          "evidence_strength": "Max PS3_supporting"
        }
      }
    }
  ]
}